RCAMU
NBIX icon

Rothschild & Co Asset Management US’s Neurocrine Biosciences NBIX Stock Holding History

Rothschild & Co Asset Management US’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$6.82M Sell
57,111
-7,308
-11% -$856K 0.1% 152
2022
Q3 		$6.84M Sell
64,419
-9,549
-13% -$969K 0.12% 143
2022
Q2 		$7.21M Sell
73,968
-4,546
-6% -$420K 0.11% 150
2022
Q1 		$7.36M Sell
78,514
-22,753
-22% -$1.93M 0.09% 168
2021
Q4 		$8.63M Buy
101,267
+12,495
+14% +$1.15M 0.1% 189
2021
Q3 		$8.51M Sell
88,772
-6,932
-7% -$655K 0.11% 192
2021
Q2 		$9.31M Sell
95,704
-10,834
-10% -$1.04M 0.11% 193
2021
Q1 		$10.4M Sell
106,538
-48,152
-31% -$5.05M 0.13% 192
2020
Q4 		$14.8M Buy
154,690
+19,647
+15% +$1.9M 0.19% 166
2020
Q3 		$13M Sell
135,043
-29,208
-18% -$3.38M 0.23% 171
2020
Q2 		$20M Sell
164,251
-45,170
-22% -$4.99M 0.3% 142
2020
Q1 		$18.1M Sell
209,421
-18,399
-8% -$1.8M 0.28% 139
2019
Q4 		$24.5M Sell
227,820
-10,544
-4% -$1.1M 0.25% 169
2019
Q3 		$21.5M Buy
238,364
+28,276
+13% +$2.64M 0.23% 178
2019
Q2 		$17.7M Buy
210,088
+60,013
+40% +$4.93M 0.19% 199
2019
Q1 		$13.2M Buy
150,075
+58,429
+64% +$4.88M 0.14% 227
2018
Q4 		$6.54M Buy
91,646
+24,879
+37% +$2.38M 0.08% 283
2018
Q3 		$8.21M Buy
+66,767
New +$7.58M 0.08% 281
2018
Q1 		– Sell
-26,525
Closed -$2.06M – 358
2017
Q4 		$2.06M Sell
26,525
-11,220
-30% -$765K 0.02% 316
2017
Q3 		$2.31M Sell
37,745
-114
-0.3% -$6.01K 0.03% 300
2017
Q2 		$1.74M Sell
37,859
-2,413
-6% -$117K 0.02% 334
2017
Q1 		$1.74M Sell
40,272
-1,876
-4% -$80.4K 0.02% 330
2016
Q4 		$1.63M Buy
42,148
+34,373
+442% +$1.56M 0.02% 352
2016
Q3 		$394K Buy
7,775
+5
+0.1% +$249 0.01% 507
2016
Q2 		$353K Buy
+7,770
New +$358K 0.01% 530
2015
Q3 		– Sell
-5,004
Closed -$239K – 349
2015
Q2 		$239K Buy
+5,004
New +$212K ﹤0.01% 335

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rothschild & Co Asset Management US's NBIX Position: Q4 2022 in Review

Rothschild & Co Asset Management US reduced its Neurocrine Biosciences (NBIX) stake by 11% in Q4 2022, selling an estimated $856K and leaving 57,111 shares worth $6.82M. The position accounts for 0.1% of the portfolio, ranked #152.

Rothschild & Co Asset Management US first reported a position in NBIX in Q2 2015 and has held it in 26 quarters since. The position peaked at $24.5M in Q4 2019. 530 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

  • Rothschild & Co Asset Management US held 57,111 shares of Neurocrine Biosciences worth $6.82M as of Q4 2022.
  • Rothschild & Co Asset Management US sold 7,308 Neurocrine Biosciences shares in Q4 2022, an estimated $856K.
  • Neurocrine Biosciences made up 0.1% of Rothschild & Co Asset Management US's portfolio in Q4 2022, its #152 holding.
  • Rothschild & Co Asset Management US first reported a position in Neurocrine Biosciences in Q2 2015 and has held it in 26 quarters since.
  • Rothschild & Co Asset Management US's Neurocrine Biosciences position peaked at $24.5M in Q4 2019.
  • 530 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Rothschild & Co Asset Management US's 13F filing for Q4 2022, filed 14 Feb 2023.